Eikon tries to follow Aktis
After Aktis's $318m flotation Eikon is a bigger proposition.
CG Oncology gets an intermediate-risk bladder boost
Readout of the Pivot-006 trial is brought forward by nearly a year.
No checkpoint glory for Acrivon
Prexasertib data worsen again, and biomarkers are up in the air.
Rakuten sheds light on its conjugate
The company secures funding to push its lead candidate towards US approval.
ASCO-GI – Astellas makes a case for its Vyloy triplet
Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.
Different dosing enlivens Enliven’s share price
ELVN-001 is made to look more like Terns’ TERN-701.
ASCO-GI – Astellas focuses on a degrader-chemo combo
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
BridgeBio Oncology shows early promise
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
The month ahead: January’s remaining events
JP Morgan approaches.
